ES2422735T3 - Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502 - Google Patents

Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502

Info

Publication number
ES2422735T3
ES2422735T3 ES07797432T ES07797432T ES2422735T3 ES 2422735 T3 ES2422735 T3 ES 2422735T3 ES 07797432 T ES07797432 T ES 07797432T ES 07797432 T ES07797432 T ES 07797432T ES 2422735 T3 ES2422735 T3 ES 2422735T3
Authority
ES
Spain
Prior art keywords
drug
risk
procedure
predicting
adverse drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07797432T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Shuen-Lu Hung
Chih-Lung Shen
Chi-Feng Chang
Hsin-Yu Lin
Wei-Hsuan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Pharmigene Inc
Original Assignee
Academia Sinica
Pharmigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2422735(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica, Pharmigene Inc filed Critical Academia Sinica
Application granted granted Critical
Publication of ES2422735T3 publication Critical patent/ES2422735T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procedimiento para evaluar, en un paciente humano, el riesgo a desarrollar una reacción adversa a unmedicamento en respuesta a un fármaco, que comprende detectar la presencia de HLA-B*1502 en una muestra obtenida del paciente y correlacionar la presencia de HLA-B*1502 en la muestra con un riesgo aumentado de desarrollo de una reacciónadversa a un medicamento en el paciente en respuesta al fármaco, en el que la reacción adversa a un medicamentoes el síndrome de Stevens-Johnson o necrólisis epidérmica tóxica y el fármaco es oxcarbazepina o licarbazepina.
ES07797432T 2006-05-11 2007-05-11 Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502 Active ES2422735T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
PCT/US2007/068782 WO2007134235A2 (en) 2006-05-11 2007-05-11 Hla alleles associated with adverse drug reactions and methods for detecting such

Publications (1)

Publication Number Publication Date
ES2422735T3 true ES2422735T3 (es) 2013-09-13

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07797432T Active ES2422735T3 (es) 2006-05-11 2007-05-11 Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502

Country Status (17)

Country Link
US (2) US7943309B2 (es)
EP (1) EP2016198B1 (es)
JP (1) JP2009536828A (es)
KR (1) KR101450348B1 (es)
CN (1) CN101454462A (es)
AU (1) AU2007249225B2 (es)
BR (1) BRPI0710436A8 (es)
CA (1) CA2651954C (es)
DK (1) DK2016198T3 (es)
ES (1) ES2422735T3 (es)
IL (1) IL194900A (es)
MY (1) MY150648A (es)
NZ (2) NZ572259A (es)
PL (1) PL2016198T3 (es)
PT (1) PT2016198E (es)
TW (1) TWI335937B (es)
WO (1) WO2007134235A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
CN102918396B (zh) * 2010-04-12 2016-05-11 中央研究院 利用人类白血球抗原(hla)筛检预测药物不良反应的方法
WO2012174723A1 (en) * 2011-06-23 2012-12-27 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Risk assessment for phenytoin-induced adverse drug reactions
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
US10041121B2 (en) * 2013-09-17 2018-08-07 Agency For Science, Technology And Research Method for detection of a genetic variant
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781B (zh) * 2014-09-26 2017-04-19 陕西佰美基因股份有限公司 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
WO2020223867A1 (zh) * 2019-05-06 2020-11-12 长庚医疗财团法人林口长庚纪念医院 评估疾病调节抗风湿药物引发严重皮肤药物不良反应风险的方法、其检测试剂盒及其用途
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
CN113308532A (zh) * 2021-05-28 2021-08-27 上海康黎诊断技术有限公司 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒，以及方法
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
EP0689609B2 (en) * 1993-03-18 2005-04-13 N.V. Innogenetics S.A. Process for typing hla-b using specific primers and probes sets
US5550039A (en) 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
BRPI0407569A (pt) * 2003-02-17 2006-02-14 Novartis Ag uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
PT2016198E (pt) 2013-07-29
AU2007249225A1 (en) 2007-11-22
TWI335937B (en) 2011-01-11
WO2007134235A3 (en) 2008-01-17
EP2016198B1 (en) 2013-05-01
WO2007134235A2 (en) 2007-11-22
JP2009536828A (ja) 2009-10-22
CN101454462A (zh) 2009-06-10
US7943309B2 (en) 2011-05-17
NZ572259A (en) 2012-03-30
EP2016198A4 (en) 2010-07-21
DK2016198T3 (en) 2013-07-15
BRPI0710436A8 (pt) 2018-06-26
IL194900A (en) 2013-02-28
TW200844238A (en) 2008-11-16
US8142999B2 (en) 2012-03-27
KR101450348B1 (ko) 2014-10-14
CA2651954C (en) 2014-02-25
CA2651954A1 (en) 2007-11-22
MY150648A (en) 2014-02-14
AU2007249225B2 (en) 2013-06-27
BRPI0710436A2 (pt) 2012-10-09
NZ597628A (en) 2013-07-26
US20110212439A1 (en) 2011-09-01
EP2016198A2 (en) 2009-01-21
IL194900A0 (en) 2009-08-03
PL2016198T3 (pl) 2013-12-31
KR20090031671A (ko) 2009-03-27
US20080145846A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
NZ597628A (en) Hla-b5801 allele associated with adverse drug reactions and methods for detecting such
DE602008004253D1 (de) Alcotestgerät
CY1119952T1 (el) Συνδυασμος μιας ινσουλινης και ενος glp-1-αγωνιστη
TW200643400A (en) Optical-based sensing devices
BRPI0909620A2 (pt) "dispositivo microfluídico para detectar a presença de um ou mais análitos em uma amostra de saliva, método para detectar a presença de um ou mais análitos em uma amostra de saliva e método para detectar em um dispositivo microfluídico um análito e uma amostra de saliva que copreende a mucina"
CR11504A (es) Deteccion mejorada de la expresion de mage-a
ATE531820T1 (de) Gesundheitszustandstest
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
BRPI0711663A2 (pt) aparelho e método de monitoramento de gás dentro de furo de sondagem auto-contido
ATE438853T1 (de) Diagnostische testvorrichtung
ATE519864T1 (de) Dna-konformation (loop-strukturen) bei normaler und anomaler genexpression
BRPI0808001A2 (pt) Dispositivo para monitoração de analisado revestido com polímero que contém nitrogênio heterocíclico e métodos de uso.
BRPI0915736A2 (pt) dispositivo para analisar uma amostra química ou biológica
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
WO2008008708A3 (en) Lung cancer diagnostic assay
WO2007114986A3 (en) Cooperative probes and methods of using them
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
BR112017023726A2 (pt) detecção de fatores de virulência microbiana na cavidade oral
BRPI0811536A8 (pt) detecção de sucinilacetona
BR112014007759A2 (pt) conjunto para condução de ensaio tendo em vista determinar a presença ou ausência de um analito em uma amostra de sangue e unidade de análise compreendendo tal conjunto
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
WO2007079284A3 (en) Lung cancer diagnostic assay
MX2009010751A (es) Composiciones y metodos de deteccion.
ITUD20040170A1 (it) Dispositivo integrato per analisi diagnostiche, e relativo procedimento